岳嶽

Andrew Yueh 2岳嶽  研究員
生技與藥物研究所
Email: andrewyueh@nhri.edu.tw

 

EDUCATION

  • Ph.D., Biochemistry, New York University School of Medicine, USA, 1997
  • M.S., Life Science, National Tsing-Hua University, Taiwan, 1988

PROFESSIONAL EXPERIENCES

  • Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2020-present)
  • Associate Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2011-2020)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan(2003-2011)
  • Postdoctoral Research Fellow, Howard Hughes Medical Institute, Department of Biochemistry and Molecular Biophysics, Columbia University, USA (1998-2003)

RESEARCH INTERESTS

  1. Molecular Virology, Antiviral Drug Discovery & Development
  2. Phage Display-based High-Throughput Screening of Monoclonal Antibody (mAb)
  3. mAb Engineering and Expression in Cell Culture
  4. mAb-based Anti-Cancer Drug Discovery & Development

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Yueh has published several high impact research articles, e.g. Cell, Genes & Development, and EMBO Journal during Ph.D. and post-doctoral training. Some of papers are highly cited. Since 2003, Dr. Yueh focused on antiviral drug research and developed several novel systems for anti-HCV and -DENV drug discovery. Several antiviral tools and platforms have been developed and published in the prestigious antiviral journals. In particular, a novel, potent HCV NS5A inhibitor, DBPR110 (also known as MB110), has been successfully developed as an anti-HCV drug candidate for clinical development. Technology transfer of DBPR110 was signed and transferred to pharmaceutical company in 2013. USFDA accepted the investigational new drug (IND) application of MB110 for the treatment of patients infected with HCV on Dec 17th, 2015. DBPR110 team was awarded silver medal for technology transfer competition in 2016 Bio-Taiwan.

Since 2015, research focus of Dr. Yueh’s lab shifted to mAb-based therapeutic drug discovery mainly targeted at cancer disease. One of drug targets is aimed at a challenging cancer novel target neurotensin receptor 1 (NTSR1), a G protein-coupled receptor. Several in-house platforms, e.g. phage display, yeast display, humanization, affinity maturation, and novel robust mAb-producing cell line were successfully developed. Several lead mAbs with sub-nM affinity to NTSR1 were obtained through panning from phage display library and mAb engineering by humanization and affinity maturation. Recently, novel anti-NTSR1 mAb based anti-cancer drug discovery approaches are ongoing as follows:

  1. Anti-NTSR1-antibody drug conjugates (ADC) carrying cytotoxins for anti-tumor therapeutic discovery.
  2. Anti-NTSR1 Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapy

AWARD

  1. Outstanding Technology Transfer Award in 2013 (by Ministry of Science and Technology) regarding the technology transfer of DBPR110, a potent hepatitis C virus inhibitor
  2. Outstanding Technology Transfer and collaboration Award (Silver medal) in 2016 (Bio Taiwan 2016) “A novel and potent small-molecule, DBPR110, against hepatitis C virus”

SELECTED PUBLICATIONS

  1. Yang CC, Hu HS, Lin HM, Wu PS, Wu RH, Tian JN, Wu SH, Tsou LK, Song JS, Chen HW, Chern JH, Chen CT and Andrew Yueh* (2019, Oct). A Novel Flavivirus Entry Inhibitor, BP34610, Discovered through High-Throughput Screening with Dengue Reporter Viruses. Antiviral Research, 172(2019)104636.
  2. Tian JN, Yang CC, Chuang CK, Tsai MH, Wu RH, Chen CT, Yueh A.* (2019, Aug). A Dengue Virus Type 2 (DENV-2) NS4B-Interacting Host Factor, SERP1, Reduces DENV-2 Production by Suppressing Viral RNA Replication. Viruses, 11(9),787.
  3. Tian, J.N.; Wu, R.H.; Chen, S.L., Chen, C.T.; Yueh, A. “Mutagenesis of the dengue virus NS4A protein reveals a novel cytosolic N-terminal domain responsible for virus-induced cytopathic effects and intramolecular interactions within the N-terminus of NS4A.” Journal of General Virology. 2019
  4. Lin, H.M.; Wu, P.S.; Hu, H.S.; Chang, W.C.; Wu, R.H.; Tian, J.N.; Chern, J.H.; Yueh, A. “Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication.” J Virol Methods. 2018, 259:10-17.
  5. Wu RH, Tsai MH, Tsai KN, Tian JN, Wu JS, Wu SY, Chern JH, Chen CH, Yueh A. Mutagenesis of Dengue Virus Protein NS2A Revealed a Novel Domain Responsible for Virus-Induced Cytopathic Effect and Interactions between NS2A and NS2B Transmembrane Segments. J. Virol. 2017, 91:e01836-16.
  6. Wu, R.H.; Tsai, M.H.; Chao, D.Y.; Yueh, A. “Scanning Mutagenesis Studies Reveal Potential Intramolecular Interaction within the C-terminal Half of Dengue Virus NS2A Involved in Viral RNA Replication and Virus Assembly/Secretion” J. Virol. 2015, 89, 4281-4295.
  7. Pu, S.Y.; Wu, R.H.; Tsai, M.H.; Yang, C.C.; Chang, C.M.; Yueh, A. “A novel approach to propagate flavivirus infectious cDNA clones in bacteria by introducing tandem repeat sequences upstream of virus genome” Journal of General Virology. 2014, 95, 1493-1503.
  8. Yang, C.C.; Hu, H.S.; Wu, R.H.; Wu, S.H.; Lee, S.J.; Jiaang, W.T.; Chern, J.H.; Huang, Z.S.; Wu, H.N.; Chang, C.M.; Yueh, A. ” A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease” Antimicrobial Agents & Chemotherapy. 2014, 58, 110-9.
  9. Yang, C.C.; Tsai, M.H.; Hu, H.S.; Pu, S.Y.; Wu, R.H.; Wu, S.H.; Lin, H.M.; Song, J.S.; Chao, Y.S.; Yueh, A. ” Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus” Antiviral Res. 2013, 98, 228-241.
  10. Lin, H.M.; Wang, J.C.; Hu, H.S.; Wu, P.S.; Wang, W.H.; Wu, S.Y.; Yang, C.C.; Wu C.P.; Yeh, T.K.; Hsu, T.A.; Jiaang, W.T.; Chao, Y.S.; Chern, J.H.; Yueh, A. “Resistance studies of a di-thiazol analogue, DBPR110, as a potential Hepatitis C virus NS5A inhibitor in replicon systems” Antimicrobial Agents & Chemotherapy. 2013, 57, 723-33.
  11. Lin, H.M.; Wang, J.C.; Hu, H.S.; Wu, P.S.; Yang, C.C.; Wu, C.P.; Pu, S.Y.; Hsu, T.A.; Jiaang, W.T.; Chao, Y.S.; Chern, J.H.; Yeh, T.K.; Yueh, A. “Resistance Analysis and Characterization of a Thiazole Analogue, BP008, as a potent Hepatitis C Virus NS5A Inhibitor ” Antimicrobial Agents & Chemotherapy. 2012, 56, 44-53.
  12. Pu, S.Y.; Wu, R.H.; Yang, C.C.; Jao, T.M.; Tsai, M.H.; Wang, J.C.; Lin, H.M.; Chao, Y.S.; Yueh, A. “Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes” J. Virol. 2011, 85, 2927-2941.
  13. Yang, C.C.; Hsieh, Y.C.; Lee, S.J.; Wu, S.H.; Liao, C.L.; Tsao, C.H.; Chao, Y.S.; Chern, J.H.; Wu, C.P.; Yueh, A. “Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay” Antimicrobial Agents & Chemotherapy. 2011, 55, 229-238.
  14. Leung, J.; Yueh, A.; Appah, F.S.; Jr, Yuan. B.; de los Santos, K.; Goff, S.P. “Interaction of Moloney murine leukemia virus matrix protein with IQGAP” EMBO J. 2006, 25, 2155-2166.
  15. Yueh, A.; Leung, J.; Bhattacharyya, S.; Perrone, L.A.; de los Santos, K.; Pu, S.Y.; Goff, S.P. “Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection” J Virol. 2006, 80, 342-352.
  16. Orlova, M.; Yueh, A.; Leung, J.; Goff, S.P. “Reverse transcriptase of Moloney murine leukemia virus binds to eukaryotic release factor 1 to modulate suppression of translational termination” 2003, 115, 319-331.
  17. Yueh, A.; Goff, S.P. “Phosphorylated serine residues and an arginine-rich domain of the moloney murine leukemia virus p12 protein are required for early events of viral infection” J Virol. 2003, 77, 1820-1829.
  18. Yuan, B.; Fassati, A.; Yueh, A.; Goff, S.P. “Characterization of Moloney murine leukemia virus p12 mutants blocked during early events of infection” J Virol. 2002, 76, 10801-1010.
  19. Yueh, A.; Schneider, R.J. “Translation by ribosome shunting on adenovirus and hsp70 mRNAs facilitated by complementarity to 18S rRNA” Genes Dev. 2000, 14, 414-421.
  20. Yueh, A.; Schneider, R.J. “Selective translation initiation by ribosome jumping in adenovirus-infected and heat-shocked cells” Genes Dev. 1996, 10, 1557-1567.

PATENT:

  1. Jyh-Haur Chern, Tsu-An Hsu, Iou-Jiun Kang, Li-Wen Wang, Chung-Chi Lee, Yen-Chun Lee, Yen-Shian Wu, Sheng-Ju Hsu, Yueh Andrew Yueh, Yu-Sheng Chao: Imidazolidinone and imidazolidinethione derivatives. May, 10 2011: US 7939523B2
  2. Andrew Yueh, Yu-Sheng Chao: Combination therapy of hepatitis virus inhibitors Taiwan ROC patent number: 148616 (2015/06/01~2033/11/07)
  3. Andrew Yueh, Yu-Sheng Chao治療C型肝炎病毒感染的醫藥組合物 China : ZL2013 80056433.2 (Apr. 8, 2019 -2039)

 

Comments are closed.